Hyperglycaemic disorders associated with PCSK9 inhibitors: a real-world, pharmacovigilance study

Keyphrases

• Adverse Events 100%
• Pharmacovigilance 100%
• PCSK9 Inhibitors 100%
• Proprotein Convertase Subtilisin/kexin Type 9 Inhibitors 100%
• Real-world Pharmacovigilance 100%
• Reporting Odds Ratio 50%
• Diabetes 33%
• Inhibitor Treatment 33%
• Statins 33%
• FDA Adverse Event Reporting System (FAERS) 33%
• Mild Hyperglycemia 33%
• Alirocumab 33%
• Evolocumab 33%
• Biological Studies 16%
• Diabetic 16%
• Non-diabetic 16%
• Hyperglycemia 16%
• Safety Profile 16%
• Information Component 16%
• Genetic Studies 16%
• Credibility Intervals 16%
• Inhibitor Agent 16%
• Drug Discontinuation 16%
• Lipid Disorders 16%
• Ezetimibe 16%
• Adverse Event Reporting System Database 16%
• Disproportionality Analysis 16%

Pharmacology, Toxicology and Pharmaceutical Science

• Adverse Event 100%
• Pharmacovigilance 100%
• Proprotein Convertase 9 100%
• Hyperglycemia 50%
• Diabetes Mellitus 33%
• Hydroxymethylglutaryl Coenzyme A Reductase Inhibitor 33%
• Alirocumab 33%
• Evolocumab 33%
• FDA Adverse Event Reporting System 33%
• Ezetimibe 16%
• Disproportionality Analysis 16%